Last updated: July 19, 2024
Sponsor: Miltenyi Biomedicine GmbH
Overall Status: Active - Recruiting
Phase
N/A
Condition
Lymphoma
Leukemia
Melanoma
Treatment
MB-CART19.1
MB-CART20.1
MB-CART2019.1
Clinical Study ID
NCT06508775
M-2022-393
2022-501648-14-00
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parenttrials at least 12 months prior to enrollment in long-term follow-up.
Patient has provided informed consent prior to enrollment.
Exclusion
Exclusion Criteria:
- No exclusion criteria
Study Design
Total Participants: 40
Treatment Group(s): 3
Primary Treatment: MB-CART19.1
Phase:
Study Start date:
May 05, 2024
Estimated Completion Date:
December 31, 2040
Study Description
Connect with a study center
Universitätsklinikum Köln
Cologne, 50937
GermanyActive - Recruiting
Universitätsmedizin Göttingen
Göttingen, 37075
GermanyActive - Recruiting
Universitätsklinikum Münster
Münster, 48149
GermanyActive - Recruiting
Universitäts-Kinderklinik Würzburg
Würzburg, 97080
GermanyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.